Istaroxime
Based on 7 publication(s) in Google Scholar
Istaroxime (PST2744) is a potent inhibitor of Na+,K+-ATPase with IC50 of 0.11 μM.
It is advisable to consider the salt form (Istaroxime hydrochloride) that retains the same biological activity.
For research use only. We do not sell to patients.
- CAS No.: 203737-93-3
- Formula: C21H32N2O3
- Molecular Weight:360.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-15718A
Istaroxime hydrochlorideCalcium Channel Activator -
HY-16592
Brefeldin AProtein Transport Inhibitor -
HY-12283
RostafuroxinATP1A1 Antognist -
HY-N0877
BufalinNa+/K+ ATPase Inhibitor -
HY-13441
(-)-BlebbistatinMyosin II ATPase Inhibitor -
HY-16589
Oligomycin AMitochondrial ATP Synthase Inhibitor -
HY-N2070
AcevaltrateNa+/K+ ATPase Inhibitor -
HY-13433
ThapsigarginER Stress Inducer -
HY-D0852
Sodium orthovanadateProtein Tyrosine/Alkaline Phosphatase Inhibitor -
HY-N6771
Cyclopiazonic acidECAs Inhibitor -
HY-N6782
OligomycinH+-ATP-Synthase Inhibitor
Publications Citing Use of MedChemExpress (MCE) Istaroxime
More- Ann Rheum Dis. 2022 Apr;81(4):544-555. [Abstract]
- Nat Commun. 2025 Aug 29;16(1):8074. [Abstract]
- Biochem Pharmacol. 2023 May:211:115516. [Abstract]
- Biochem Pharmacol. 2020 Oct:180:114122. [Abstract]
- J Am Heart Assoc. 2021 Jul 20;10(14):e018833. [Abstract]
- Front Pharmacol. 2020 Dec 14:11:606097. [Abstract]
- PNAS Nexus. 2023 Dec 22;3(1):pgad453. [Abstract]
Biological Activity
Description
IC50 & Target
IC50: 0.11 μM (Na+,K+-ATPase)[1]
In Vitro
Istaroxime acting as a positive inotropic compound through the inhibition of the Na+,K+-ATPase[2]. Istaroxime (PST2744) inhibits the Na+/K+-ATPase activity from dog kidney with an IC50 value of 0.43 ± 0.15 μM. Inhibition of Na+/K+-ATPase activity in preparations from guinea pig kidney yielded potencies of 8.5 μM for PST2744[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 203737-93-3
-
Molecular Weight 360.49
-
Formula C21H32N2O3
-
SMILES
O=C1CC[C@@]2([H])[C@]3([H])CC([C@@]4([H])C/C(CC[C@]4(C)[C@@]3([H])CC[C@@]21C)=N/OCCN)=O
-
Synonyms
PST2744
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Ann Rheum Dis
Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis. [Abstract]2022 Apr;81(4):544-555. PMID: 34853001 -
Nat Commun
NEXN protects against vascular calcification by promoting SERCA2 SUMOylation and stabilization. [Abstract]2025 Aug 29;16(1):8074. PMID: 40883305 -
Biochem Pharmacol
Periplocin targets low density lipoprotein receptor-related protein 4 to attenuate osteoclastogenesis and protect against osteoporosis. [Abstract]2023 May:211:115516. PMID: 36966936 -
Biochem Pharmacol
Natural cardenolides suppress coronaviral replication by downregulating JAK1 via a Na+/K+-ATPase independent proteolysis. [Abstract]2020 Oct:180:114122. PMID: 32592721 -
J Am Heart Assoc
2021 Jul 20;10(14):e018833. PMID: 34219467 -
Front Pharmacol
Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives. [Abstract]2020 Dec 14:11:606097. PMID: 33519469 -
PNAS Nexus
Mechanisms for cardiac calcium pump activation by its substrate and a synthetic allosteric modulator using fluorescence lifetime imaging. [Abstract]2023 Dec 22;3(1):pgad453. PMID: 38222469
Purity & Documentation
References
[1]. Gobbini M, et al. Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship. J Med Chem. 2008 Aug 14;51(15):4601-8. [Content Brief]
[2]. Gobbini M, et al. Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold. Bioorg Med Ch [Content Brief]
[3]. Micheletti R, et al. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther. 2002 Nov;303(2):592-600. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Istaroxime Related Classifications
HY-15718 Related Classifications
Powered by Bioz